Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I.

Journal Article (Journal Article)

Saliva contains factors that inhibit infection with the human immunodeficiency virus type 1 (HIV-1) in vitro. One of these factors was recently identified as secretory leukocyte protease inhibitor (SLPI), a salivary protein which blocked HIV-1 infectivity of monocytes and primary T cells at physiologic concentrations (J Clin Invest 1995; 96: 456). Here, we confirm and extend the original report by demonstrating that SLPI protects primary monocytes and peripheral blood mononuclear cells against infection with HIV-1 Ba-L, IIIB and NL4-3. Thus, SLPI may provide a natural barrier against oral transmission of HIV-1.

Full Text

Duke Authors

Cited Authors

  • Shugars, DC; Sauls, DL; Weinberg, JB

Published Date

  • May 1997

Published In

Volume / Issue

  • 3 Suppl 1 /

Start / End Page

  • S70 - S72

PubMed ID

  • 9456661

International Standard Serial Number (ISSN)

  • 1354-523X

Digital Object Identifier (DOI)

  • 10.1111/j.1601-0825.1997.tb00379.x


  • eng

Conference Location

  • Denmark